HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The Bile Acid Receptor GPBAR1 Regulates the M1/M2 Phenotype of Intestinal Macrophages and Activation of GPBAR1 Rescues Mice from Murine Colitis.

Abstract
GPBAR1 (TGR5 or M-BAR) is a G protein-coupled receptor for secondary bile acids that is highly expressed in monocytes/macrophages. In this study, we aimed to determine the role of GPBAR1 in mediating leukocyte trafficking in chemically induced models of colitis and investigate the therapeutic potential of BAR501, a small molecule agonist for GPBAR1. These studies demonstrated that GPBAR1 gene ablation enhanced the recruitment of classically activated macrophages in the colonic lamina propria and worsened the severity of inflammation. In contrast, GPBAR1 activation by BAR501 reversed intestinal inflammation in the trinitrobenzenesulfonic acid and oxazolone models by reducing the trafficking of Ly6C+ monocytes from blood to intestinal mucosa. Exposure to BAR501 shifted intestinal macrophages from a classically activated (CD11b+, CCR7+, F4/80-) to an alternatively activated (CD11b+, CCR7-, F4/80+) phenotype, reduced the expression of inflammatory genes (TNF-α, IFN-γ, IL-1β, IL-6, and CCL2 mRNAs), and attenuated the wasting syndrome and severity of colitis (≈70% reduction in the Colitis Disease Activity Index). The protective effect was lost in Gpbar1-/- mice. Exposure to BAR501 increased the colonic expression of IL-10 and TGF-β mRNAs and the percentage of CD4+/Foxp3+ cells. The beneficial effects of BAR501 were lost in Il-10-/- mice. In a macrophage cell line, regulation of IL-10 by BAR501 was GPBAR1 dependent and was mediated by the recruitment of CREB to its responsive element in the IL-10 promoter. In conclusion, GPBAR1 is expressed in circulating monocytes and colonic macrophages, and its activation promotes a IL-10-dependent shift toward an alternatively activated phenotype. The targeting of GPBAR1 may offer therapeutic options in inflammatory bowel diseases.
AuthorsMichele Biagioli, Adriana Carino, Sabrina Cipriani, Daniela Francisci, Silvia Marchianò, Paolo Scarpelli, Daniele Sorcini, Angela Zampella, Stefano Fiorucci
JournalJournal of immunology (Baltimore, Md. : 1950) (J Immunol) Vol. 199 Issue 2 Pg. 718-733 (07 15 2017) ISSN: 1550-6606 [Electronic] United States
PMID28607110 (Publication Type: Journal Article)
CopyrightCopyright © 2017 by The American Association of Immunologists, Inc.
Chemical References
  • 6-ethyl-3,7-dihydroxycholan-24-ol
  • Antigens, Ly
  • Ccl2 protein, mouse
  • Chemokine CCL2
  • Cholestanols
  • Gpbar1 protein, mouse
  • IL10 protein, mouse
  • Interleukin-1beta
  • Interleukin-6
  • Ly-6C antigen, mouse
  • Receptors, G-Protein-Coupled
  • Tumor Necrosis Factor-alpha
  • interleukin-6, mouse
  • Interleukin-10
  • Oxazolone
  • Trinitrobenzenesulfonic Acid
Topics
  • Animals
  • Antigens, Ly (genetics, immunology)
  • Cell Line
  • Cell Movement
  • Chemokine CCL2 (genetics, immunology)
  • Cholestanols (administration & dosage, pharmacology)
  • Colitis (chemically induced, immunology, metabolism)
  • Gene Expression Regulation (immunology)
  • Inflammation (immunology)
  • Interleukin-10 (deficiency, genetics, immunology)
  • Interleukin-1beta (genetics, immunology)
  • Interleukin-6 (genetics, immunology)
  • Intestinal Mucosa (immunology)
  • Macrophage Activation
  • Macrophages (drug effects, immunology)
  • Mice
  • Mucous Membrane (immunology)
  • Oxazolone (administration & dosage)
  • Phenotype
  • Promoter Regions, Genetic
  • Receptors, G-Protein-Coupled (agonists, deficiency, genetics, metabolism)
  • T-Lymphocytes, Regulatory (drug effects, immunology)
  • Trinitrobenzenesulfonic Acid (administration & dosage)
  • Tumor Necrosis Factor-alpha (genetics, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: